WHO ICTRP trial
Safety and efficacy of rapamycin (Sirolimus) in the treatment of PI3K-AKT1-mTOR…
ChiCTR2100042574 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2100042574 |
|---|---|
| Public title | Safety and efficacy of rapamycin (Sirolimus) in the treatment of PI3K-AKT1-mTOR related overgrowth syndrome |
| Scientific title | Safety and efficacy of rapamycin (Sirolimus) in the treatment of PI3K-AKT1-mTOR related overgrowth syndrome |
| Primary sponsor | Beijing Jishuitan Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | PIK3CA related overgrowth syndrome |
| Interventions | affected side:use rapamycin |
| Registration date | Jan 23, 2021 |
| Target size | affected side:35 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: